Clinical trial
Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
NCT04469829 is registered in ClinicalTrials.gov with Universita di Verona as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
- Lead sponsor
- Universita di Verona
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- August 1, 2020
- Completion date
- December 31, 2022
- Enrollment
- 70 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.